AG真人官方

C. Frank Bennett, EVP and Chief Scientific Officer of Ionis Pharmaceuticals (IONS), reported option exercise and share sale transactions on 08/18/2025. He was granted or exercised a non-qualified stock option with a $32.60 exercise price covering 10,000 shares exercisable from 01/03/2023 and expiring 01/02/2032, which increased his direct common stock holdings to 103,466 shares. On the same date, he sold 10,000 shares pursuant to a Rule 10b5-1 trading plan adopted May 13, 2025, for a weighted average price of $43.9776 per share (sales occurred at prices between $43.75 and $44.25). Following the sale, his reported direct common stock ownership was 93,466 shares. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on behalf of Mr. Bennett.

Ionis Pharmaceuticals Form 144 filing summary 鈥� This notice reports a proposed sale of 16,000 shares of the issuer's common stock through Stifel Nicolaus & Company, Inc. with an aggregate market value of $703,642.00. The sale is scheduled approximately for 08/18/2025 on Nasdaq. The filing lists prior acquisitions underlying the shares: an option exercise on 01/03/2022 totaling 28,869 shares, restricted stock units granted on 01/15/2017 for 7,537 shares, and restricted stock units on 01/15/2016 for 6,373 shares. The table for sales during the past three months shows Nothing to Report. Several identifying fields (filer CIK/CCC and the named person for whose account the sale is proposed) are not provided in the content.

Ionis Pharmaceuticals director B. Lynne Parshall sold 5,000 shares of Ionis common stock on 08/06/2025 under a pre-established Rule 10b5-1 trading plan adopted May 6, 2025. The filings report two sales: 4,600 shares at a weighted-average price of $41.8685 (individual trade prices ranged from $41.50 to $42.36) and 400 shares at a weighted-average price of $42.6275 (individual trade prices ranged from $42.56 to $42.83). Following the reported transactions, the Form 4 shows beneficial ownership figures of 86,744 shares and 86,344 shares respectively. The reporting person is identified as a director and the sales were executed pursuant to the disclosed trading plan.

Filing type: Form 144 notice for Ionis Pharmaceuticals, Inc. (IONS).

Proposed sale: 10,000 shares of Common Stock through Stifel Nicolaus & Company Inc (501 N Broadway, St. Louis, MO) on 08/06/2025, with an aggregate market value of $419,292.00. The filing lists 159,391,229 shares outstanding.

Acquisition details: 42,223 shares were acquired as Restricted Stock Units on 01/15/2017; payment: Cash. The filing shows "Nothing to Report" for securities sold in the past 3 months. The filer identity/CIK and submission contact fields are not provided in the form content.

Ionis Pharmaceuticals (IONS) filed a Form 4 stating that EVP & Chief Clinical Development Officer Eugene Schneider sold 9,549 common shares on 08/04/2025 pursuant to a pre-arranged Rule 10b5-1 trading plan adopted 05/02/2025. The weighted-average sale price was $42.8004, with individual trades executed between $42.315 and $43.45. Gross proceeds are roughly $0.41 million.

Following the disposition, Schneider directly owns 51,507 shares; the sale reduced his direct stake by approximately 15.6 % (from 61,056 shares). No derivative securities were involved. The filing is a routine Section 16 disclosure and does not affect the company鈥檚 operations or guidance.